Adenovirus infection and disease in recipients of hematopoietic cell transplantation. Issue 6 (December 2019)

• Record Type: Journal Article
• Authors: Dailey Garnes, Natalie J.M.; Ragoonanan, Dristhi; Aboulhosn, Aya
• Is Part Of: Current opinion in infectious diseases. Volume 32:Issue 6(2019)
• Publication Date: 2019-12
• Subjects: adenovirus -- antiviral therapy -- screening -- stem-cell transplant -- virus-specific T cells; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Review Literature -- Periodicals; 616.905
• DOI: 10.1097/QCO.0000000000000605
• Languages: English
• ISSNs: 0951-7375

Abstract

Abstract : Purpose of review: To provide an update on risk factors associated with adenovirus (ADV) infection in patients after hematopoietic cell transplant (HCT) and on options for ADV monitoring and treatment in the setting of HCT. Recent findings: Among patients undergoing HCT, ADV infection continues to be more common amongst those receiving a T-cell-depleted or graft other than from a matched-related donor. Among children undergoing HCT, reactivation in the gastrointestinal tract appears to be the most common source, and the virus is detectable by quantitative PCR in the stool before it is detectable in the blood. Thus, screening for the virus in the stool of these children may allow for preemptive therapy to reduce mortality. Brincidofovir, although still not approved by any regulatory agency, remains a potential agent for preemptive therapy and for salvage in cases not responding to cidofovir. Rapidly generated off-the-shelf virus-specific T cells may facilitate adoptive cell therapy in populations with a special need and previously not eligible for adoptive cell therapy, such as cord blood recipients. Summary: ADV infection continues to adversely affect survival in HCT recipients. Screening stool in children and preemptive therapy may reduce mortality. Brincidofovir and adoptive T-cell therapy remain potential options for treatment.